Recreational abuse of newly emerging "club drugs" including atypical hallucinogens, which is exacerbated by internet websites, is a significant and growing national problem. Abuse of these drugs among adolescents and young adults is a particular concern. A series of studies in human volunteers will provide new information about the pharmacological mechanisms of action, comparative pharmacology, and abuse liability of three mechanistically different hallucinogen compounds that are of concern to national authorities and about which there are major gaps in our current understanding: salvinorin A (a ? opioid agonist), N,N-dimethyltryptamine (DMT, a 5-HT2A agonist), and dextromethorphan (an NMDA antagonist). For all three compounds, dose-effect studies using low to high doses in participants with histories of hallucinogen drug abuse will provide new information about subjective effects, psychiatric symptoms, behavioral/cognitive impairment, physiological effects, relative abuse liability, and possible persisting toxic consequences of use. Pharmacological mechanisms of action will be investigated by examining the effects of selective receptor antagonists and by systematically comparing pairs of drugs acting at different receptor sites. Specifically, the first three studies will focus on two short-acting, atypical hallucinogens: salvinorin A and DMT. The first study will use a double- blind, double-dummy design to compare the effects of inhaled vaporized salvinorin A and intravenous DMT across a wide range of doses and measures, characterizing both robust and subtle differences between the two compounds. The second and third studies will further explore mechanisms of action by examining interactions of both drugs with naltrexone (a selective opioid receptor antagonist) and ketanserin (a selective 5-HT2A antagonist). The subsequent three studies will focus on the relatively longer-acting compound dextromethorphan, which is a noncompetitive NMDA-antagonist found in over-the-counter cough and cold medications and abused at high doses as a hallucinogen. The fourth study will compare the dose-effects of oral dextromethorphan with oral psilocybin (a classic 5-HT2A-mediated hallucinogen with a duration of action similar to dextromethorphan) characterizing both robust and subtle differences between the two compounds. The fifth and sixth studies will further explore the mechanisms of action of dextromethorphan (vs. psilocybin) by examining interactions with naltrexone (opioid antagonists are used clinically to treat dextromethorphan overdose) and ketanserin. Overall, this research program exploring the comparative pharmacology and specific mechanisms of action of salvinorin A, DMT, and dextromethorphan will have relevance to the development of prevention and treatment strategies for the abuse of these emerging abused hallucinogen drugs. Regarding public health more generally, this research has potentially wide-ranging implications for understanding the neurobiological basis of psychiatric and neurological disorders that involve the ? opioid, 5- HT, and NMDA receptor pathways.
Recreational abuse of club drugs including hallucinogens is a significant and growing national problem, particularly in adolescents and young adults, and internet websites encourage abuse by describing how some of these drugs can be readily obtained as naturally-occurring plants or in over-the-counter cough and cold medications. This project will investigate the physical, behavioral, cognitive, and subjectively rewarding effects of three abused hallucinogens with different mechanisms of action in the brain, and will also examine whether certain pharmacological compounds can block the effects of each drug. The project has important implications for prevention and treatment strategies for the abuse of these hallucinogen drugs, as well as for understanding the brain mechanisms of psychiatric and neurological disorders.
|Reissig, Chad J; Harrison, Joseph A; Carter, Lawrence P et al. (2015) Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology (Berl) 232:871-83|
|MacLean, Katherine A; Johnson, Matthew W; Reissig, Chad J et al. (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) 226:381-92|
|Carter, Lawrence P; Kleykamp, Bethea A; Griffiths, Roland R et al. (2013) Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology (Berl) 226:53-63|
|Johnson, Matthew W; Griffiths, Roland R (2013) Comparative abuse liability of GHB and ethanol in humans. Exp Clin Psychopharmacol 21:112-23|
|Carter, Lawrence P; Reissig, Chad J; Johnson, Matthew W et al. (2013) Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug Alcohol Depend 128:206-13|
|Reissig, Chad J; Carter, Lawrence P; Johnson, Matthew W et al. (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl) 223:1-15|
|Johnson, Matthew W; Sewell, R Andrew; Griffiths, Roland R (2012) Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 123:132-40|
|MacLean, Katherine A; Johnson, Matthew W; Griffiths, Roland R (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25:1453-61|
|Johnson, Matthew W; MacLean, Katherine A; Reissig, Chad J et al. (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150-5|
|Griffiths, Roland R; Johnson, Matthew W; Richards, William A et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649-65|
Showing the most recent 10 out of 85 publications